Inter Partes Review's Day Has Come For Pharma IP Cases
Law360, New York (August 22, 2014, 10:16 AM EDT) -- The Patent Trial and Appeal Board issued its first final written decisions on June 20, 2014, in four inter partes reviews of pharmaceutical-related patents. The four decisions effectively invalidated all 58 of the challenged patent claims spread across four patents owned by Merck & Cie and the South Alabama Medical Science Foundation, both of whom previously accused Italian biotech firm Gnosis SpA of infringement.
SAMSF owns three of the patents, which are licensed to Merck, which in turn owns the fourth patent generally relating to the active metabolites of folate in combination with other vitamins to treat various conditions associated with folate...
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
Create custom alerts for specific article and case topics and so much more!